Matches in SemOpenAlex for { <https://semopenalex.org/work/W2559766601> ?p ?o ?g. }
- W2559766601 endingPage "e59" @default.
- W2559766601 startingPage "e51" @default.
- W2559766601 abstract "BackgroundThe full extent to which childhood pneumococcal conjugate vaccines (PCV) can indirectly reduce illness in unvaccinated populations is not known. We aimed to estimate the magnitude and timing of indirect effects of PCVs on invasive pneumococcal disease.MethodsIn this systematic review and meta-analysis, we searched bibliographic databases for non-randomised quasi-experimental or observational studies reporting invasive pneumococcal disease changes following PCV introduction in unvaccinated populations (studies published Sept 1, 2010, to Jan 6, 2016), updating the previous systematic review of the same topic (studies published Jan 1, 1994, to Sept 30, 2010). Two reviewers extracted summary data by consensus. We used a Bayesian mixed-effects model to account for between-study heterogeneity to estimate temporal indirect effects by pooling of invasive pneumococcal disease changes by serotype and serogroup.FindingsData were extracted from 70 studies included in the previous review and 172 additional studies, covering 27 high-income and seven middle-income countries. The predicted mean times to attaining a 90% reduction in invasive pneumococcal disease were 8·9 years (95% credible interval [CrI] 7·8–10·3) for grouped serotypes contained in the seven-valent PCV (PCV7), and 9·5 years (6·1–16·6) for the grouped six additional serotypes contained in the 13-valent PCV (PCV13) but not in PCV7. Disease due to grouped serotypes contained in the 23-valent pneumococcal polysaccharide vaccine (PPV23) decreased at similar rates per year in adults aged 19–64 years (relative risk [RR] 0·85, 95% CrI 0·75–0·95) and 65 years and older (0·87, 0·84–0·90). However, we noted no changes in either group in invasive pneumococcal disease caused by the additional 11 serotypes covered by PPV23 but not PCV13.InterpretationPopulation childhood PCV programmes will lead, on average, to substantial protection across the whole population within a decade. This large indirect protection should be considered when assessing vaccination of older age groups.FundingPolicy Research Programme of the Department of Health, England. The full extent to which childhood pneumococcal conjugate vaccines (PCV) can indirectly reduce illness in unvaccinated populations is not known. We aimed to estimate the magnitude and timing of indirect effects of PCVs on invasive pneumococcal disease. In this systematic review and meta-analysis, we searched bibliographic databases for non-randomised quasi-experimental or observational studies reporting invasive pneumococcal disease changes following PCV introduction in unvaccinated populations (studies published Sept 1, 2010, to Jan 6, 2016), updating the previous systematic review of the same topic (studies published Jan 1, 1994, to Sept 30, 2010). Two reviewers extracted summary data by consensus. We used a Bayesian mixed-effects model to account for between-study heterogeneity to estimate temporal indirect effects by pooling of invasive pneumococcal disease changes by serotype and serogroup. Data were extracted from 70 studies included in the previous review and 172 additional studies, covering 27 high-income and seven middle-income countries. The predicted mean times to attaining a 90% reduction in invasive pneumococcal disease were 8·9 years (95% credible interval [CrI] 7·8–10·3) for grouped serotypes contained in the seven-valent PCV (PCV7), and 9·5 years (6·1–16·6) for the grouped six additional serotypes contained in the 13-valent PCV (PCV13) but not in PCV7. Disease due to grouped serotypes contained in the 23-valent pneumococcal polysaccharide vaccine (PPV23) decreased at similar rates per year in adults aged 19–64 years (relative risk [RR] 0·85, 95% CrI 0·75–0·95) and 65 years and older (0·87, 0·84–0·90). However, we noted no changes in either group in invasive pneumococcal disease caused by the additional 11 serotypes covered by PPV23 but not PCV13. Population childhood PCV programmes will lead, on average, to substantial protection across the whole population within a decade. This large indirect protection should be considered when assessing vaccination of older age groups." @default.
- W2559766601 created "2016-12-16" @default.
- W2559766601 creator A5010352674 @default.
- W2559766601 creator A5022950275 @default.
- W2559766601 creator A5031812482 @default.
- W2559766601 creator A5055928551 @default.
- W2559766601 creator A5058932170 @default.
- W2559766601 creator A5086651355 @default.
- W2559766601 creator A5089167457 @default.
- W2559766601 creator A5089919855 @default.
- W2559766601 date "2017-01-01" @default.
- W2559766601 modified "2023-10-11" @default.
- W2559766601 title "Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis" @default.
- W2559766601 cites W1588977108 @default.
- W2559766601 cites W1920731750 @default.
- W2559766601 cites W1921011725 @default.
- W2559766601 cites W1975191235 @default.
- W2559766601 cites W1977198231 @default.
- W2559766601 cites W1981257809 @default.
- W2559766601 cites W1984046165 @default.
- W2559766601 cites W1997718238 @default.
- W2559766601 cites W2008526009 @default.
- W2559766601 cites W2010463009 @default.
- W2559766601 cites W2010575292 @default.
- W2559766601 cites W2025200855 @default.
- W2559766601 cites W2037106151 @default.
- W2559766601 cites W2052296516 @default.
- W2559766601 cites W2052353073 @default.
- W2559766601 cites W2053889461 @default.
- W2559766601 cites W2063964640 @default.
- W2559766601 cites W2092545077 @default.
- W2559766601 cites W2097129414 @default.
- W2559766601 cites W2103351962 @default.
- W2559766601 cites W2121369371 @default.
- W2559766601 cites W2132652740 @default.
- W2559766601 cites W2139709122 @default.
- W2559766601 cites W2141828980 @default.
- W2559766601 cites W2146088408 @default.
- W2559766601 cites W2149176649 @default.
- W2559766601 cites W2157583453 @default.
- W2559766601 cites W2157823046 @default.
- W2559766601 cites W2163434103 @default.
- W2559766601 cites W2168137709 @default.
- W2559766601 cites W2170521505 @default.
- W2559766601 cites W2170555729 @default.
- W2559766601 cites W2177080107 @default.
- W2559766601 cites W2184687076 @default.
- W2559766601 cites W2220164129 @default.
- W2559766601 cites W2341014512 @default.
- W2559766601 cites W4294215472 @default.
- W2559766601 doi "https://doi.org/10.1016/s2214-109x(16)30306-0" @default.
- W2559766601 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27955789" @default.
- W2559766601 hasPublicationYear "2017" @default.
- W2559766601 type Work @default.
- W2559766601 sameAs 2559766601 @default.
- W2559766601 citedByCount "135" @default.
- W2559766601 countsByYear W25597666012016 @default.
- W2559766601 countsByYear W25597666012017 @default.
- W2559766601 countsByYear W25597666012018 @default.
- W2559766601 countsByYear W25597666012019 @default.
- W2559766601 countsByYear W25597666012020 @default.
- W2559766601 countsByYear W25597666012021 @default.
- W2559766601 countsByYear W25597666012022 @default.
- W2559766601 countsByYear W25597666012023 @default.
- W2559766601 crossrefType "journal-article" @default.
- W2559766601 hasAuthorship W2559766601A5010352674 @default.
- W2559766601 hasAuthorship W2559766601A5022950275 @default.
- W2559766601 hasAuthorship W2559766601A5031812482 @default.
- W2559766601 hasAuthorship W2559766601A5055928551 @default.
- W2559766601 hasAuthorship W2559766601A5058932170 @default.
- W2559766601 hasAuthorship W2559766601A5086651355 @default.
- W2559766601 hasAuthorship W2559766601A5089167457 @default.
- W2559766601 hasAuthorship W2559766601A5089919855 @default.
- W2559766601 hasBestOaLocation W25597666011 @default.
- W2559766601 hasConcept C10389963 @default.
- W2559766601 hasConcept C121117317 @default.
- W2559766601 hasConcept C126322002 @default.
- W2559766601 hasConcept C187212893 @default.
- W2559766601 hasConcept C203014093 @default.
- W2559766601 hasConcept C22070199 @default.
- W2559766601 hasConcept C23131810 @default.
- W2559766601 hasConcept C2776152631 @default.
- W2559766601 hasConcept C2778866548 @default.
- W2559766601 hasConcept C2779134260 @default.
- W2559766601 hasConcept C2781253189 @default.
- W2559766601 hasConcept C3020803494 @default.
- W2559766601 hasConcept C44249647 @default.
- W2559766601 hasConcept C523546767 @default.
- W2559766601 hasConcept C54355233 @default.
- W2559766601 hasConcept C71924100 @default.
- W2559766601 hasConcept C86803240 @default.
- W2559766601 hasConcept C95190672 @default.
- W2559766601 hasConceptScore W2559766601C10389963 @default.
- W2559766601 hasConceptScore W2559766601C121117317 @default.
- W2559766601 hasConceptScore W2559766601C126322002 @default.
- W2559766601 hasConceptScore W2559766601C187212893 @default.
- W2559766601 hasConceptScore W2559766601C203014093 @default.
- W2559766601 hasConceptScore W2559766601C22070199 @default.